|
Supreme Court Likely to Keep ‘Safe Harbor’ Broad, Boosting Generic and Biosimilar Makers: Expert
The country’s highest court is likely to mull Hatch-Waxman’s safe-harbor provision now that the U.S. Court of Appeals for the Federal Circuit has issued contradictory rulings on when the law allows drugmakers to use others’ patents without fear of infringement.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
SCOTUS “Pay-for-Delay” Decision Provides Roadmap for Case-by-Case CrackdownMomenta: SCOTUS Must Settle Uncertainty in Safe Harbor Landscape, Rule Against Amphastar Teva Prepping for Potential $2 Billion Loss in Protonix Patent FlapApotex Breaks From Pack, Offers Strong Critique of Pay-for-Delay to SCOTUS
|
Subscribe
Archives